Here are 1-3 brief analogies for Pulse Biosciences (PLSE):

• Imagine a medical device company like Cutera or InMode, but instead of lasers or radiofrequency, they use ultra-short electrical pulses for non-thermal, targeted cell treatments.
• Like an Intuitive Surgical, but instead of robotic surgery, their platform uses nano-pulse electrical energy to precisely target and remove cells for various medical conditions.
• A medical technology innovator akin to Shockwave Medical, but utilizing precise electrical nano-pulses instead of sound waves for non-thermal, targeted cell clearance.

• CellFX System: A tunable, software-enabled, and console-based platform that delivers nano-second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue for treating various medical conditions.

Pulse Biosciences (PLSE) primarily sells its CellFX System to healthcare providers and medical practices, rather than directly to individuals. The company's major customers can be categorized as follows:

• Dermatology Clinics and Practices: This category includes individual dermatologists and group practices that specialize in the diagnosis and treatment of skin conditions. They utilize the CellFX System for various dermatological applications, such as the clearance of benign lesions.
• Plastic Surgery Clinics and Medical Spas: Plastic surgeons, cosmetic clinics, and medical spas constitute another key customer segment. They employ the CellFX System for aesthetic procedures that require precise, non-thermal cell targeting capabilities.
• Hospitals and Academic Medical Centers: Larger healthcare institutions and university-affiliated medical centers may also be customers, integrating the CellFX System into relevant departments for a broader range of medical conditions or for clinical research and development.

Burke T. Barrett, Chief Executive Officer

Burke T. Barrett was appointed President and Chief Executive Officer of Pulse Biosciences in May 2024. He previously spent approximately 18 years at CardioFocus, Inc., including three years as CEO and President, where he was instrumental in building an electrophysiology ablation device and a global commercial company. Mr. Barrett was also part of the teams that successfully took two companies public, Biofield Corp. and Cyberkinetics Neurotechnology Systems, Inc., and served as an officer for both Cyberonics, Inc. and Cyberkinetics.

Jon Skinner, Chief Financial Officer

Jon Skinner was appointed Chief Financial Officer of Pulse Biosciences in February 2025. Prior to joining Pulse Biosciences, he served as Vice President, FP&A and Investor Relations at Copeland, a private equity-backed industrial company. He also held the position of Vice President, Finance and Corporate Development at Imperative Care, a venture-backed medical technology company, and served as interim CFO for Kandu Health during its spin-out and fundraising. Mr. Skinner's experience also includes leadership roles at Teleflex (NYSE: TFX), where he led finance and operations for the Interventional Urology Business Unit and facilitated 25 M&A transactions, and working on Axalta Coating Systems' (NYSE: AXTA) carve-out and IPO.

Darrin R. Uecker, Chief Technology Officer & Director

Darrin R. Uecker was appointed Chief Technology Officer of Pulse Biosciences in September 2022, having previously served as the company's Chief Executive Officer & President from September 2015 to September 2022. He brings over 30 years of experience in the medical device field and is a named inventor on more than 70 patents. Before his tenure at Pulse Biosciences, Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc. He also served as CEO and President of Gynesonics, Inc., and held executive-level roles at CyberHeart, Inc., Conceptus, Inc., RITA Medical Systems, Inc., and Computer Motion, Inc.

Mitchell E. Levinson, Chief Strategy Officer

Mitchell E. Levinson was appointed Chief Strategy Officer of Pulse Biosciences in August 2021. With over 30 years of experience, he has developed and launched novel medical device technologies across numerous medical disciplines. Mr. Levinson co-founded and served as the startup CEO for Cerebrotech Medical Systems and was the first employee and startup CEO for Zeltiq Aesthetics, which was acquired by Allergan in 2017. He also held executive R&D positions at Thermage and BioSurgical Corporation and serves on the boards of directors for several medical technology startup companies. Mr. Levinson is an inventor on over 50 issued U.S. patents.

David Kenigsberg, Chief Medical Officer of Electrophysiology

David Kenigsberg, M.D., joined Pulse Biosciences in December 2024 as Chief Medical Officer of Electrophysiology. He is a practicing cardiac electrophysiologist with a strong focus on treating atrial fibrillation. Dr. Kenigsberg is also the founder of Florida Heart Rhythm Specialists and Ft. Lauderdale Heart & Rhythm Surgical Center.

The key risks to Pulse Biosciences (PLSE) business include regulatory challenges and the efficacy of its core technology, a limited operating history with an ongoing need for capital, and the challenges of market acceptance amid competition.

Regulatory Challenges and Efficacy of Core Technology

Pulse Biosciences has faced significant hurdles in obtaining broad regulatory clearances for its Nano-Pulse Stimulation (NPS) technology. In 2018, the company failed to secure an FDA 510(k) clearance for general soft tissue ablation, a clearance it had described as foundational for future applications. The application was withdrawn, with indications that the company could not demonstrate the device's substantial equivalence in terms of safety and effectiveness compared to existing devices. Furthermore, in February 2020, the FDA issued a "Not Substantially Equivalent" letter for its CellFX System, again highlighting issues with the data provided to demonstrate equivalence. While the company has since achieved specific FDA clearances, such as for sebaceous hyperplasia in 2022 and approval for a pivotal IDE study for paroxysmal atrial fibrillation in late 2025, the history of regulatory setbacks and questions regarding the efficacy of the technology for broader applications present a significant ongoing risk. The stringent and evolving regulatory environment for novel medical devices generally poses a threat to the swift market entry of new products.

Limited Operating History, Lack of Significant Revenue, and Capital Needs

Pulse Biosciences operates with a limited history of commercial operations and has not yet established a significant revenue stream. The company has consistently reported operating losses, with no product revenue generated in recent periods, including Q1 2024, Q1 2025, and Q4 2025, while incurring substantial net losses (e.g., $72.78 million for the full year 2025). This necessitates a continuous reliance on equity sales and other forms of financing to fund its research and development, personnel, and market expansion efforts. This ongoing need for additional capital could lead to further dilution of existing shareholders' equity, and funding needs and potential dilution are considered central risks to the company.

Market Acceptance and Competition

Introducing a novel bioelectric medicine technology like Nano-Pulse Stimulation requires overcoming potential skepticism from both the medical community and patients to achieve widespread market acceptance. The company faces intense competition from established players in the medical equipment industry who possess greater resources and could rapidly develop competing technologies. For instance, some analyses have suggested that the potential for aesthetic applications of the technology is insignificant, and the dermatological/aesthetic market is already competitive and limited. The heavy reliance on a single technology platform and the potential for slow adoption by healthcare providers could restrict the company's growth trajectory. Pulse Biosciences' stock is also noted for its high volatility and risk profile.

Pulse Biosciences (PLSE) primarily offers its CellFX System, which utilizes Nano-Pulse Stimulation (NPS) technology. The initial commercial use of the CellFX System focuses on a range of dermatologic conditions that demonstrate high patient and practitioner demand for improved aesthetic outcomes. The company is also actively developing its nPulse technology for the treatment of atrial fibrillation and surgical soft tissue ablation.

The addressable markets for Pulse Biosciences' products and services can be estimated through the broader medical aesthetic devices market and the neurostimulation devices market.

• Global Medical Aesthetic Devices Market: This market, which includes energy-based devices like the CellFX System, was valued at approximately USD 14,901.7 million in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 11.9% from 2023 to 2030. Another report indicates the global market for medical aesthetic devices was valued at USD 20.1 billion in 2023 and is projected to reach USD 37.9 billion by the end of 2029, growing at a CAGR of 11.3% from 2024 to 2029. North America held the largest share in the medical aesthetic devices market.
• Global Neurostimulation Devices Market: For potential applications such as atrial fibrillation, the global neurostimulation devices market reached USD 7.2 billion in 2023. This market is forecasted to grow to USD 25.2 billion by 2034, with a CAGR of 12.1% from 2025 to 2034. North America dominated this market with a 41.2% share in 2024, with the U.S. market specifically reaching USD 3 billion in 2024.

Pulse Biosciences (PLSE) is focusing on several key areas to drive future revenue growth over the next 2-3 years, primarily leveraging its Nano-Pulse Stimulation (NPS) technology across various medical applications.

1. Commercialization of the nPulse Cardiac Catheter System for Atrial Fibrillation: The company is actively advancing its nanosecond Pulsed Field Ablation (nsPFA) platform into late-stage clinical development for atrial fibrillation (AF). Pulse Biosciences received FDA approval to commence a pivotal IDE study for the nPulse Cardiac Catheter System for paroxysmal AF in Q4 2025, with patient enrollment expected to be completed in 2026. Promising European feasibility study results, showing high procedural success and freedom from atrial arrhythmia, support this initiative. The company also plans CE mark submissions in the second half of 2026, with potential approval in 2027, which would allow for market entry in Europe.

2. Commercialization of the nPulse Cardiac Surgical System (NANOCLAMP AF) for Atrial Fibrillation: Alongside the catheter system, Pulse Biosciences is progressing with its nPulse Cardiac Surgical System, including the NANOCLAMP AF pivotal study for treating AF in concomitant surgical procedures. The company is expanding and accelerating IDE site activation to complete patient enrollment in 2026. This represents a significant opportunity in the cardiac ablation market.

3. Expanded Commercialization and Reimbursement for the nPulse Vybrance Percutaneous Electrode System for Benign Thyroid Nodules: Pulse Biosciences has received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System for soft tissue ablation. The company is driving early targeted adoption of the nPulse Vybrance percutaneous electrode system, with benign thyroid nodule treatment as the initial use case. The PRECISE-BTN study for benign thyroid nodules is ongoing, with plans to complete initial enrollment and expand further. Long-term clinical durability data has shown significant volume reduction in treated nodules, with high patient satisfaction. Securing therapeutic indications and reimbursement for this system is expected within the next 1-2 years, which will be crucial for revenue growth.

4. Expansion of Nano-Pulse Stimulation (NPS) Technology into New Therapeutic Areas, particularly Malignant Thyroid Tumors: Beyond benign conditions, Pulse Biosciences is actively exploring the application of its nsPFA technology for malignant thyroid tumors. The company has initiated a research collaboration with the University of Texas MD Anderson Cancer Center to evaluate the use of nsPFA for both benign and malignant thyroid tumors. Initial patient enrollments have begun in a multi-center feasibility study for T1N0M0 papillary thyroid microcarcinoma. This expansion into oncology represents a new potential growth avenue for the company's proprietary technology.

Share Issuance

• In July 2021, Pulse Biosciences completed a private placement where Chairman Robert W. Duggan purchased 3,048,780 shares of common stock, involving an $8.4 million cash investment and the conversion of approximately $41.6 million in debt and accrued interest, totaling about $50 million.
• Around February 2026, the company established a new at-the-market (ATM) equity distribution agreement with TD Securities (USA) LLC, allowing it to sell common stock with an aggregate offering price of up to approximately $59.98 million. This new agreement replaced a previous ATM program.
• A shelf registration statement was filed around February 2026, enabling the company to offer up to $200,000,000 of various securities, including common stock, on a "from time to time" basis.

Inbound Investments

• Pulse Biosciences received a significant investment through a $50 million private placement in July 2021. This included an $8.4 million cash injection and the conversion of $41.6 million in prior indebtedness from Robert W. Duggan, the company's Chairman.

Capital Expenditures

• For the fourth quarter of 2025, Pulse Biosciences reported capital expenditures of $105,000.
• Over the trailing twelve months preceding Q4 2025, capital expenditures amounted to approximately $315,000.
• Capital expenditures primarily support the advancement of the company's proprietary nPulse nanosecond Pulsed Field Ablation (nsPFA) technology and related clinical programs and commercialization efforts.